Ferric carboxymaltose meets primary goal of anemia treatment study

07/12/2013 | PharmaTimes (U.K.)

Ferinject, or intravenous ferric carboxymaltose, met the main goal of a clinical trial by significantly reducing the use of erythropoiesis-stimulating agents and transfusions among patients with non-dialysis-dependent chronic kidney disease. More than 600 patients participated in the international, 56-week study. They received either oral iron or 1,000 milligrams of ferric carboxymaltose initially and more as needed.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID